Daily Cardiology Research Analysis
Analyzed 184 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out today. A mechanistic study identified an endothelial SR-B1–CXCL10–CXCR3 axis driving T‑cell recruitment and diastolic dysfunction in HFpEF, suggesting a new immuno-vascular target. A multicenter randomized trial found that left bundle branch area pacing did not meet non-inferiority to biventricular pacing for CRT response, informing device strategy. Population pharmacokinetic modeling during VA-ECMO provided actionable ticagrelor dosing recommendations.
Research Themes
- Immuno-vascular mechanisms in HFpEF (endothelial SR-B1 and T-cell cardiotropism)
- Optimization of cardiac resynchronization therapy: LBB area pacing vs biventricular pacing
- Model-informed antiplatelet dosing during VA-ECMO
Selected Articles
1. Microvascular endothelial scavenger receptor class B type I protects against heart failure with preserved ejection fraction by inhibiting T-cell cardiotropism.
This mechanistic study identifies an endothelial SR-B1–CXCL10–CXCR3 axis that promotes CXCR3+ T-cell recruitment to the heart and worsens diastolic dysfunction in HFpEF. Endothelial SR-B1 restoration rescues phenotype in mice, and human HFpEF tissue and plasma show activation of this axis, nominating CXCL10 and SR-B1 signaling as translational targets.
Impact: Revealing a causal endothelial-immune axis in HFpEF bridges vascular biology and immunity, providing mechanistic clarity and actionable targets in a syndrome with limited therapies.
Clinical Implications: Although preclinical, CXCL10 levels and SR-B1 pathway activity may support future risk stratification and biomarker-guided trials. Therapeutic modulation (e.g., CXCL10/CXCR3 blockade, SR-B1 restoration) could be explored to attenuate diastolic dysfunction.
Key Findings
- SR-B1 is predominantly expressed in CMECs and is downregulated in HFpEF.
- Endothelial SR-B1 deficiency aggravates diastolic dysfunction and remodeling; AAV1-mediated SR-B1 reconstitution rescues the phenotype.
- Loss of SR-B1 increases CXCL10 secretion, activates inflammatory CMEC subclusters, and drives CXCR3+ T-cell cardiotropism via endothelial IRF1 activation.
- Human HFpEF shows activation of the SR-B1–CXCL10–CXCR3 axis; plasma CXCL10 is independently associated with higher HFpEF prevalence.
Methodological Strengths
- Multimodal approach combining endothelial-specific genetics, AAV1 rescue, single-cell transcriptomics, and lineage tracing
- Human translational corroboration with tissue and plasma biomarker associations
Limitations
- Preclinical models predominate; causal biomarker–outcome links in humans remain to be proven
- Extent of generalizability across HFpEF phenotypes and comorbidities is unknown
Future Directions: Prospective human studies to validate CXCL10/SR-B1 as biomarkers; early-phase trials of CXCL10/CXCR3 pathway inhibitors or SR-B1 augmentation to modify diastolic function and clinical outcomes.
Cardiac microvascular endothelial cells (CMECs) dysfunction is a well-recognized mediator of heart failure with preserved ejection fraction (HFpEF), but the underlying mechanism remains unclear. Here we find that scavenger receptor class B type I (SR-B1) is predominantly expressed in CMECs and decreased significantly in HFpEF. Endothelial-specific SR-B1 deficiency exacerbates cardiac pathological remodeling and diastolic dysfunction in HFpEF, which can be prevented by endothelial SR-B1 reconstitution through adeno-associated virus serotype 1 (AAV1)-mediated delivery in endothelial-specific SR-B1-deficient mice. Single-cardiac-endothelial-cell transcriptomics and lineage-tracing system reveal that inflammatory CMECs subcluster activation is responsible for the deteriorating HFpEF progression induced by endothelial SR-B1 loss, rather than endothelial-to-mesenchymal transition. Mechanistically, SR-B1 loss drives increased CXCL10 secretion, which orchestrates CMECs activation and CXCR3-positive T-cell cardiotropism to promote diastolic dysfunction-a process associated with endothelial IRF1 activation. Most importantly, the SR-B1-CXCL10-CXCR3 axis is activated in human HFpEF cardiac tissue, and the elevated CXCL10 level in plasma is independently associated with a higher HFpEF prevalence. This study uncovers that activation of the SR-B1-CXCL10-CXCR3 axis in CMECs aggravates HFpEF pathogenesis through the accumulation of CXCR3-positive T-cells in hearts.
2. Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial.
In this multicenter randomized non-inferiority trial (n=176), LBB area pacing did not meet non-inferiority to biventricular pacing for 6‑month CRT response in typical LBBB, though both strategies achieved high response rates and similar safety. These data calibrate expectations for conduction system pacing and inform device selection.
Impact: First randomized head-to-head evaluation of LBBAP vs BiVP for CRT response provides practice-informing evidence amid rapid uptake of conduction system pacing.
Clinical Implications: BiVP remains the reference CRT strategy in typical LBBB when aiming for robust response; LBBAP may be considered but should not be presumed equivalent. Patient selection, operator expertise, and long-term outcomes warrant consideration.
Key Findings
- Primary endpoint achieved in 94.6% (BiVP) vs 89.7% (LBBAP); non-inferiority for LBBAP not met (RR 0.95; 95% CI 0.88–1.02).
- Clinical composite score improved in 77% (BiVP) vs 68% (LBBAP); LVESV reduction ≥15% in 85% vs 79%, respectively.
- Adverse events and heart failure hospitalization rates were similar; crossovers occurred in 14.9%.
Methodological Strengths
- Multicenter randomized design with predefined non-inferiority margin
- Clinically meaningful composite response and echocardiographic endpoints with 12‑month follow-up
Limitations
- Non-inferiority not met; study may be underpowered for certain secondary endpoints
- Crossover rate (14.9%) and modest follow-up horizon may influence estimates
Future Directions: Head-to-head trials powered for clinical outcomes and durability; stratified analyses by substrate, operator learning curves, and device programming; cost-effectiveness and quality-of-life assessments.
BACKGROUND AND AIMS: Conduction system pacing has emerged as an alternative to biventricular pacing (BiVP) for cardiac resynchronization therapy (CRT). The left-bundle CRT trial evaluated whether left-bundle branch area pacing (LBBAP) is non-inferior to BiVP in patients eligible for CRT. METHODS: The left-bundle CRT trial was a multi-centre, randomized, investigator-initiated, and non-inferiority study. Patients with guideline-based CRT indications and left-bundle branch block per Strauss criteria were randomized to BiVP-CRT or LBBAP-CRT. The primary endpoint was the proportion of patients with a positive CRT response at 6-months, defined as either an improved clinical composite score (CCS) or a ≥15% reduction in left ventricular end-systolic volume. The non-inferiority margin was the lower bound of the 95% confidence interval (CI) and was set at 10%. Patients were followed for 12-months; secondary endpoints included echocardiographic, clinical, and quality-of-life outcomes. RESULTS: The baseline characteristics of the 176 patients randomized to BiVP-CRT (n=84) or LBBAP-CRT (n=92) were similar, except for a wider intrinsic QRS in the LBBAP group: median 172 ms [IQR 158-184] vs. 165 ms [152-180]; P=0.04. Crossovers occurred in 26 patients (14.9%). In the intention-to-treat analysis, the primary endpoint was achieved in 94.6% of BiVP-CRT and 89.7% of LBBAP-CRT patients (RR 0.95; 95% CI 0.88-1.02), not meeting non-inferiority. CCS improved in 77% and 68% of patients randomized to BiVP-CRT and LBBAP-CRT, respectively and 85% and 79% had a ≥15% reduction in left ventricular end-systolic volume. Rates of adverse events and heart failure hospitalization were similar between groups. CONCLUSIONS: In CRT candidates with typical LBBB, LBBAP-CRT was not shown to be non-inferior to BiVP-CRT. Both strategies yielded high response rates and similar clinical outcomes.
3. Population Pharmacokinetics of Ticagrelor during Veno-Arterial ECMO in Acute Coronary Syndrome: Model-Informed Dosing Simulations.
In 20 VA-ECMO patients with ACS, paired ON/OFF ECMO PK showed reduced ticagrelor clearance and increased volume of distribution on support. Model-informed simulations favored a 120–135 mg loading dose followed by 60 mg once daily to achieve target troughs, while 90 mg once daily often exceeded the upper limit.
Impact: Provides the first quantitative, model-based dosing recommendations for ticagrelor during VA-ECMO, a high-risk setting with altered disposition and sparse guidance.
Clinical Implications: Clinicians may consider reduced once-daily maintenance dosing (60 mg qd after 120–135 mg load) during VA-ECMO to stay within target exposure, pending PK/PD and outcome validation. ECMO flow may modulate drug disposition and should be considered in dosing decisions.
Key Findings
- VA-ECMO was associated with reduced ticagrelor clearance and increased volume of distribution; higher flow rates correlated with lower volumes of distribution.
- Joint parent–metabolite NONMEM model using 225 paired concentrations characterized ECMO effects on disposition.
- Monte Carlo simulations supported a 120–135 mg loading dose followed by 60 mg once-daily maintenance to keep troughs 180–360 ng/mL; 90 mg qd often exceeded the target.
Methodological Strengths
- Paired ON- vs OFF-ECMO sampling in the same patients reduces interindividual variability
- Robust population PK modeling with parent–metabolite linkage and Monte Carlo simulations
Limitations
- Small sample size (n=20) limits precision and generalizability
- No pharmacodynamic platelet inhibition or clinical outcome validation
Future Directions: Prospective PK/PD studies with platelet function and bleeding/ischemic outcomes; evaluation across different ECMO circuits and flow settings; exploration of alternative antiplatelet strategies in VA-ECMO.
Although patients with acute coronary syndrome supported by veno-arterial extracorporeal membrane oxygenation (VA-ECMO) have a high risk of thrombosis and bleeding, antiplatelet pharmacology in this setting is not well defined. This prospective observational study investigated the population pharmacokinetics of ticagrelor and its active metabolite AR-C124910XX and explored model-informed dosing strategies among this population. Paired pharmacokinetic sampling was performed at predefined time points during ON- and OFF-ECMO periods. Plasma concentrations were measured using a validated liquid chromatography-tandem mass spectrometry assay and analyzed with NONMEM to develop a joint parent-metabolite model and evaluate the effects of VA-ECMO status and flow rate on ticagrelor disposition. Monte Carlo simulations of various ECMO flow-rate scenarios examined alternative loading and maintenance regimens using prespecified trough concentrations of 180-360 ng/mL, as derived from previous exposure-response and exposure-bleeding analyses in non-ECMO populations. A total of 225 ticagrelor and 225 metabolite concentrations (127 ON-ECMO and 98 OFF-ECMO) from 20 patients were analyzed. VA-ECMO support was associated with reduced ticagrelor clearance and increased volume of distribution, while higher flow rates were associated with decreased volumes of distribution. In simulations, an initial loading dose of 120-135 mg followed by a 60 mg maintenance dose once daily most consistently maintained predicted trough concentrations within the target range during VA-ECMO, whereas 90 mg once daily frequently exceeded the upper bound. These findings indicate that VA-ECMO substantially altered ticagrelor pharmacokinetics and provided quantitative, model-informed support for reduced once daily dosing strategies; however, further pharmacokinetic-pharmacodynamic and outcome studies are needed to confirm these findings.